Therapy-recalcitrant folliculitis decalvans controlled successfully with adalimumab

Alhameedy, Meshal M; Alsantali, Adel

doi:10.4103/ijt.ijt_92_19

Cited by 15 publications

(20 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, adalimumab showed good efficacy and safety in a case series of 23 patients with refractory FD ( 16 ). In contrast to the current study results, significant improvement was rapidly observed from 2–3 months after initiation of anti-TNFα ( 11 – 14 , 16 ). However, it is important to note that the dose of adalimumab used in Iorizzo et al’s study ( 16 ) was comparable to the dose indicated to treat hidradenitis suppurativa (subcutaneous injections of 160 mg at week 0, 80 mg at week 2, and 80 mg every other week) that higher than the dose used in the current study.…”

Section: Discussioncontrasting

confidence: 99%

“…Indeed, 1 patient is still on the treatment after 7.5 years of follow-up. Few studies have reported the use of anti-TNFα patients with refractory FD (11)(12)(13)(14). Recently, adalimumab showed good efficacy and safety in a case series of 23 patients with refractory FD (16).…”

Section: Discussionmentioning

confidence: 99%

“…However, it is important to note that the dose of adalimumab used in Iorizzo et al’s study ( 16 ) was comparable to the dose indicated to treat hidradenitis suppurativa (subcutaneous injections of 160 mg at week 0, 80 mg at week 2, and 80 mg every other week) that higher than the dose used in the current study. In addition, when treatment duration was limited to 3–4 months, patients relapsed rapidly, suggesting that disease control is obtained only with longer treatment ( 12 , 14 ). Anti-TNFα showed, in addition, good result in a case of chronic non-scarring folliculitis ( 17 ).…”

Section: Discussionmentioning

confidence: 99%

“…However, relapses are often observed after discontinuation of treatment (8)(9)(10). TNFα inhibitors have showed promise for the management of HS, and anti-TNFα has been used successfully in some cases of refractory FD (11)(12)(13)(14). Nevertheless, the clinical efficacy of this strategy needs to be evaluated.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and Safety of Tumour Necrosis Factor-α Antagonists for Folliculitis Decalvans: A Retrospective Case-series Pilot Study

Dupont¹,

Eyraud²,

Milpied³

et al. 2023

Acta Derm Venereol

View full text Add to dashboard Cite

Folliculitis decalvans is a chronic inflammatory skin disease leading to scarring alopecia. Management of this disabling disease is difficult and no treatment is currently approved. Current knowledge regarding the pathogenesis of folliculitis decalvans suggests the benefit of using anti-tumour necrosis factor-α. This pilot study aimed to evaluate the clinical efficacy of anti-tumour necrosis factor-α for management of folliculitis decalvans. A single-centre retrospective pilot study included patients with refractory folliculitis decalvans treated by tumour necrosis factor-α inhibitors. An Investigator’s Global Assessment (IGA) score was designed and validated to assess the efficacy of the therapy. Response to treatment was considered good to excellent when an IGA ≤ 2 was obtained at month 12. Eleven patients were included, with a mean time from diagnosis of folliculitis decalvans to the introduction of infliximab (n = 9) or adalimumab (n = 2) of 8.55 ± 1.26 years. Nine patients had failed on at least 2 lines of systemic therapies before starting anti-tumour necrosis factor-α. The median IGA score at baseline was 3. At the end of follow-up, 5 patients were considered responders. Overall, the safety profile of anti-tumour necrosis factor-α was good. The results suggest that the clinical benefit of anti-tumour necrosis factor-α is obtained after at least 6 months of treatment. However, further prospective studies are needed to confirm these results.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and Safety of Tumour Necrosis Factor-α Antagonists for Folliculitis Decalvans: A Retrospective Case-series Pilot Study

Dupont¹,

Eyraud²,

Milpied³

et al. 2023

Acta Derm Venereol

View full text Add to dashboard Cite

show abstract

“…Off‐label use of Adalimumab had been reported in multiple neutrophilic dermatosis, including pyoderma gangrenosum and dissecting cellulitis 14,15 . Due to fear of preserving the remaining hair follicles and decreasing inflammation, our team initiated Adalimumab subcutaneous injections following HS prescribing protocol 10–13 …”

Section: Discussionmentioning

confidence: 99%